United Therapeutics UTHR Nebulized Tyvaso — Gross Profit
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's nebulized tyvaso — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's nebulized tyvaso — gross profit?
- United Therapeutics (UTHR) reported nebulized tyvaso — gross profit of $118.6M in Q1 2026.
- How has United Therapeutics's nebulized tyvaso — gross profit changed year-over-year?
- United Therapeutics's nebulized tyvaso — gross profit decreased by 23.6% year-over-year, from $155.3M to $118.6M.
- What is the long-term trend for United Therapeutics's nebulized tyvaso — gross profit?
- Over 3 years (2021 to 2025), United Therapeutics's nebulized tyvaso — gross profit has grown at a -1.3% compound annual growth rate (CAGR), from $580.7M to $558.5M.
- What does nebulized tyvaso — gross profit mean?
- This metric represents the residual profit after deducting the direct cost of sales from the total revenue generated by the nebulized drug product. It serves as a key indicator of the product's inherent profitability and the company's ability to maintain healthy margins on its core therapeutic offerings. A robust gross profit margin for this segment is essential for funding ongoing research and development and general corporate operations.